Neurocrine Biosciences Announces Board Member’s Retirement
Neurological and endocrine-based diseases specialist Neurocrine Biosciences Inc. has announced that W. Thomas Mitchell will be retiring from the board of directors just prior to the 2016 annual meeting of shareholders. Mitchell has been a member of the board for over 13 years, serving in various capacities on the audit, compensation, nominating and corporate governance committees.
You may also be interested in...
Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study
Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.